NEW YORK (TheStreet) -- Radius Health (RDUS - Get Report) stock soared by 25.44% to $33.87 on heavy trading volume on Monday, after biotechnology company Amgen (AMGN) released data from a late-stage clinical trial. 

The data indicated that women who used Amgen's osteoporosis drug romosozumab experienced a 73% decline in their risk of developing a spine fracture compared to a control group. 

The report boosted shares of Radius Health, as the company's own experimental osteoporosis drug abaloparatide caused an 86% decline in the risk of developing a spine fracture compared to a control group. 

Based in Waltham, MA, Radius Health is a biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases.

About 5.96 million shares of Radius Health were traded today, well above the company's average trading volume of roughly 1.14 million shares per day.

RDUS Chart RDUS data by YCharts